| Hematological abnormalities in COVID-19: a narrative review A Rahman, R Niloofa, U Jayarajah, S De Mel, V Abeysuriya, ... The American journal of tropical medicine and hygiene 104 (4), 1188, 2021 | 136 | 2021 |
| Molecular pathogenic pathways in extranodal NK/T cell lymphoma S de Mel, SSS Hue, AD Jeyasekharan, WJ Chng, SB Ng Journal of hematology & oncology 12, 1-18, 2019 | 122 | 2019 |
| Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells BM Pickering, S De Mel, M Lee, M Howell, F Habens, CL Dallman, ... Oncogene 26 (8), 1166-1177, 2007 | 108 | 2007 |
| Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis PJ Teoh, O An, TH Chung, JY Chooi, SHM Toh, S Fan, W Wang, BTH Koh, ... Blood, The Journal of the American Society of Hematology 132 (12), 1304-1317, 2018 | 107 | 2018 |
| Implications of heterogeneity in multiple myeloma S de Mel, SH Lim, ML Tung, WJ Chng BioMed research international 2014 (1), 232546, 2014 | 92 | 2014 |
| STAT3: a promising therapeutic target in multiple myeloma PSY Chong, WJ Chng, S de Mel Cancers 11 (5), 731, 2019 | 79 | 2019 |
| A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore N Ngoi, J Lim, S Ow, WY Jen, M Lee, W Teo, J Ho, R Sundar, ML Tung, ... ELSEVIER, 2020 | 59 | 2020 |
| Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS CMM Wai, S Chen, T Phyu, S Fan, SM Leong, W Zheng, LCY Low, ... Haematologica 107 (8), 1864, 2022 | 58 | 2022 |
| Favipiravir in COVID-19 SL Seneviratne, V Abeysuriya, S De Mel, I De Zoysa, R Niloofa International Journal of Progressive Sciences and Technologies 19 (2), 143-5, 2020 | 58 | 2020 |
| Immunotherapy in multiple myeloma CY Soekojo, M Ooi, S de Mel, WJ Chng Cells 9 (3), 601, 2020 | 47 | 2020 |
| Atypical lymphocyte count correlates with the severity of dengue infection CSH Clarice, V Abeysuriya, S de Mel, B Uvindu Thilakawardana, ... PLoS One 14 (5), e0215061, 2019 | 46 | 2019 |
| Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection CYC Yip, ES Yap, S De Mel, WZY Teo, CT Lee, S Kan, MCC Lee, ... British Journal of Haematology 190 (1), 33, 2020 | 43 | 2020 |
| Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma EHL Chan, LP Koh, J Lee, S De Mel, A Jeyasekharan, X Liu, T Tang, ... Cancer medicine 8 (10), 4626-4632, 2019 | 43 | 2019 |
| The genomics and molecular biology of natural killer/T-cell lymphoma: opportunities for translation S De Mel, GST Soon, Y Mok, TH Chung, AD Jeyasekharan, WJ Chng, ... International Journal of Molecular Sciences 19 (7), 1931, 2018 | 42 | 2018 |
| Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma S de Mel, MBM Rashid, XY Zhang, J Goh, CT Lee, LM Poon, EHL Chan, ... Blood Cancer Journal 10 (1), 9, 2020 | 33 | 2020 |
| The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations S de Mel, JB Li, MB Abid, T Tang, HM Tay, WC Ting, LM Poon, TH Chung, ... Cytometry Part B: Clinical Cytometry 94 (1), 159-168, 2018 | 31 | 2018 |
| A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma XP Tian, SY Ma, KH Young, CK Ong, YH Liu, ZH Li, QL Zhai, HQ Huang, ... Blood, The Journal of the American Society of Hematology 138 (6), 452-463, 2021 | 29 | 2021 |
| High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma KL Lewis, LH Jakobsen, D Villa, KE Smedby, KJ Savage, TA Eyre, ... Journal of Clinical Oncology 41 (35), 5376-5387, 2023 | 28 | 2023 |
| Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis LL Chong, YY Soon, CY Soekojo, M Ooi, WJ Chng, S de Mel Critical Reviews in Oncology/Hematology 159, 103211, 2021 | 28 | 2021 |
| An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma J Goh, S De Mel, MM Hoppe, MB Mohd Abdul Rashid, XY Zhang, ... Science Translational Medicine 14 (667), eabn7824, 2022 | 25 | 2022 |
